123 related articles for article (PubMed ID: 17918663)
1. Abnormal motor movements associated with combining psychostimulants and atypical antipsychotics in children.
Sharp B; Perdue C
CNS Spectr; 2007 Sep; 12(9):659-62. PubMed ID: 17918663
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.
Linton D; Barr AM; Honer WG; Procyshyn RM
Curr Psychiatry Rep; 2013 May; 15(5):355. PubMed ID: 23539465
[TBL] [Abstract][Full Text] [Related]
3. Stimulant and atypical antipsychotic medications for children placed in foster homes.
Linares LO; Martinez-Martin N; Castellanos FX
PLoS One; 2013; 8(1):e54152. PubMed ID: 23326588
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole induced acute dystonia after discontinuation of a stimulant medication.
McLaren JL; Cauble S; Barnett RJ
J Clin Psychopharmacol; 2010 Feb; 30(1):77-8. PubMed ID: 20075654
[No Abstract] [Full Text] [Related]
5. Acute dystonic reaction in an adolescent on risperidone when a concomitant stimulant medication is discontinued.
Keshen A; Carandang C
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):867-70. PubMed ID: 18315457
[TBL] [Abstract][Full Text] [Related]
6. Dystonia with combined antipsychotic and stimulant treatment.
Levine JB; Deneys ML; Benjamin S
J Am Acad Child Adolesc Psychiatry; 2007 Jun; 46(6):665-666. PubMed ID: 17513979
[No Abstract] [Full Text] [Related]
7. Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Coughlin CG; Cohen SC; Mulqueen JM; Ferracioli-Oda E; Stuckelman ZD; Bloch MH
J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):611-7. PubMed ID: 26402485
[TBL] [Abstract][Full Text] [Related]
8. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
9. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
Farmer CA; Epstein JN; Findling RL; Gadow KD; Arnold LE; Kipp H; Kolko DJ; Butter E; Schneider J; Bukstein OG; McNamara NK; Molina BS; Aman MG
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):117-124. PubMed ID: 27348211
[TBL] [Abstract][Full Text] [Related]
10. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Aman MG; Binder C; Turgay A
J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD.
Bali V; Kamble PS; Aparasu RR
J Atten Disord; 2019 Jan; 23(2):163-172. PubMed ID: 26494504
[TBL] [Abstract][Full Text] [Related]
12. [Antipsychotic agents and stimulants: a judicious combination?].
de Jong MH; Eussen ML; van Gool AR
Tijdschr Psychiatr; 2010; 52(1):57-61. PubMed ID: 20054798
[TBL] [Abstract][Full Text] [Related]
13. Risperidone-to-methylphenidate switch reaction in children: three cases.
Sabuncuoglu O
J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
[TBL] [Abstract][Full Text] [Related]
14. Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers.
Winterstein AG; Soria-Saucedo R; Gerhard T; Correll CU; Olfson M
J Clin Psychiatry; 2017 Jul; 78(7):e744-e781. PubMed ID: 28686819
[TBL] [Abstract][Full Text] [Related]
15. Stimulant-atypical antipsychotic interaction and acute dystonia.
Benjamin E; Salek S
J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):510-2. PubMed ID: 15908830
[No Abstract] [Full Text] [Related]
16. Evaluation of dystonia in children and adolescents treated with atomoxetine within the Truven MarketScan database: a retrospective cohort study.
Meyers KJ; Upadhyaya HP; Goodloe R; Kryzhanovskaya LA; Liles-Burden MA; Kellier-Steele NA; Mancini M
Expert Opin Drug Saf; 2018 May; 17(5):467-473. PubMed ID: 29625537
[TBL] [Abstract][Full Text] [Related]
17. The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder.
Ashton H; Gallagher P; Moore B
J Psychopharmacol; 2006 Sep; 20(5):602-10. PubMed ID: 16478756
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacotherapy for conduct disorder in children and adolescents].
Levy T; Bloch Y
Harefuah; 2012 Jul; 151(7):421-6, 435, 434. PubMed ID: 23002695
[TBL] [Abstract][Full Text] [Related]
19. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.
Weiss M; Panagiotopoulos C; Giles L; Gibbins C; Kuzeljevic B; Davidson J; Harrison R
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):575-82. PubMed ID: 19877982
[TBL] [Abstract][Full Text] [Related]
20. The association between medication for attention-deficit/hyperactivity disorder and cancer.
Steinhausen HC; Helenius D
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):208-13. PubMed ID: 23560601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
